PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLacosamide
Vimpat(lacosamide)
Lacosamide, Motpoly, Vimpat (lacosamide) is a small molecule pharmaceutical. Lacosamide was first approved as Vimpat on 2008-08-29. It is used to treat epilepsy, lennox gastaut syndrome, partial epilepsies, and tonic-clonic epilepsy in the USA. It has been approved in Europe to treat epilepsy and partial epilepsies.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Lacosamide, Motpoly, Vimpat (discontinued: Lacosamide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lacosamide
Tradename
Company
Number
Date
Products
MOTPOLY XRAucta PharmaceuticalsN-216185 RX2023-05-04
3 products, RLD, RS
VIMPATUCBN-022254 RX2008-10-28
1 products, RLD, RS
VIMPATUCBN-022255 RX2010-04-20
1 products, RLD, RS
VIMPATUCBN-022253 RX2008-10-28
4 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lacosamideANDA2024-12-15
lacosamide oral solutionANDA2024-11-19
motpoly xrNew Drug Application2024-10-17
vimpatNew Drug Application2024-09-23
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N03: Antiepileptics
— N03A: Antiepileptics
— N03AX: Other antiepileptics in atc
— N03AX18: Lacosamide
HCPCS
No data
Clinical
Clinical Trials
121 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EpilepsyD004827EFO_0000474G40.92102681560
SeizuresD012640HP_0002069G40.4—10193940
Partial epilepsiesD004828EFO_0004263——355618
Peripheral nervous system diseasesD010523HP_0009830G64—361—8
Migraine disordersD008881EFO_0003821G43—151—7
Traumatic brain injuriesD000070642—S06———112
Brain injuriesD001930—S06.9———112
Heart arrestD006323EFO_0009492I46———112
ComaD003128HP_0001259R40.2———112
Respiratory insufficiencyD012131HP_0002093J96.9———1—1
Show 12 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic neuropathiesD003929EFO_1000783——57——10
Status epilepticusD013226EFO_0008526G41——3—25
PainD010146EFO_0003843R52—13——4
Complex partial epilepsyD017029EFO_1000877———3——3
DementiaD003704EFO_0003862F03——1——1
Psychophysiologic disordersD011602—F45.9——1——1
SchizophreniaD012559EFO_0000692F20——1——1
DepressionD003863—F33.9——1——1
Anxiety disordersD001008EFO_0006788F41.1——1——1
Somatoform disordersD013001—F45——1——1
Show 3 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeuralgiaD009437EFO_0009430——4———4
Postherpetic neuralgiaD051474———3———3
AlcoholismD000437EFO_0003829F10.111———2
Alcohol drinkingD000428EFO_0004329—11———2
Brain neoplasmsD001932EFO_0003833C71—1——12
GliomaD005910EFO_0000520——1——12
OsteoarthritisD010003EFO_0002506M15-M19—2———2
Amyotrophic lateral sclerosisD000690HP_0007354G12.2111———1
Motor neuron diseaseD016472EFO_0003782G12.211———1
SclerosisD012598——11———1
Show 8 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———7————7
Renal insufficiencyD051437HP_0000083N191———12
Alcoholic intoxicationD000435——1————1
PancreatitisD010195HP_0001733K851————1
Opioid-related disordersD009293EFO_0005611F111————1
Chronic painD059350HP_0012532—1————1
Abdominal painD015746HP_0002027R10.91————1
HyperalgesiaD006930——1————1
Chronic pancreatitisD050500EFO_0000342K86.11————1
PancreaticoduodenectomyD016577——1————1
Show 1 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug resistant epilepsyD000069279——————11
Acute kidney injuryD058186HP_0001919N17————11
PharmacokineticsD010599——————11
Partial epilepsy motorD020938EFO_1001089—————11
Financial stressD000086522——————11
Breast feedingD001942——————11
Autoimmune diseases of the nervous systemD020274——————11
Hashimoto diseaseD050031EFO_0003779E06.3————11
EncephalitisD004660HP_0002383—————11
AcidosisD000138EFO_1000014E87.2————11
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLacosamide
INNlacosamide
Description
Lacosamide is a N-acyl-amino acid.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1
Identifiers
PDB—
CAS-ID175481-36-4
RxCUI—
ChEMBL IDCHEMBL58323
ChEBI ID—
PubChem CID219078
DrugBankDB06218
UNII ID563KS2PQY5 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lacosamide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
23,677 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use